Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide PharmaphorumArmed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.Metabolic & GLP-1Read full story pharminent July 23, 2026 (Last updated: July 23, 2026) Pharmaphorum Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugNext: Lilly’s Retatrutide Hits 22.6% Weight Loss in Phase 3, But Cardiovascular Benefit Remains Elusive Related Stories Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug pharminent July 23, 2026 Regulatory Celcuity gains FDA approval for closely watched breast cancer drug pharminent July 15, 2026 Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026
